-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Reinstates Outperform on Compass Therapeutics, Announces $9 Price Target

Benzinga·07/01/2025 15:42:50
Listen to the news
Raymond James analyst Sean McCutcheon reinstates Compass Therapeutics (NASDAQ:CMPX) with a Outperform and announces $9 price target.